| Study groups |
|
GG vs. AA |
GA vs. AA |
GG/GA vs. AA |
GG vs. GA/AA |
| N* |
OR (95% CI) |
P﹩ |
OR (95% CI) |
P﹩ |
OR (95% CI) |
P﹩ |
OR (95% CI) |
P﹩ |
| Total |
17 |
1.21(1.12-1.60) ‡ |
<0.001 |
1.06(0.99-1.36) |
0.536 |
1.16 (1.03-1.46) ‡ |
<0.001 |
1.12 ( 0.95-1.31)‡ |
<0.001 |
| Cancer type |
|
|
|
|
|
|
|
|
|
| Hepatocellular |
1 |
1.43(1.10-1.87) |
0.851 |
1.29(0.99-1.68) |
0.771 |
1.36(0.92-1.75) |
0.796 |
1.17 (0.96-1.37) |
0.920 |
| Gastric |
6 |
1.22 (1.02-1.46) |
0.523 |
1.82 (1.16-2.87) |
0.704 |
1.13 (1.01-1.26) |
0.711 |
1.25(1.06-2.39) |
0.642 |
| Colorectal |
7 |
1.13 (1.01-1.26)‡ |
0.020 |
0.805(0.50-1.30)‡ |
0.006 |
0.86 (0.54-1.35)‡ |
0.006 |
1.08(0.80- 1.45) |
0.215 |
| Esophagus |
2 |
1.00(0.24-4.30)‡ |
<0.001 |
1.45(1.11-1.91) |
0.146 |
1.19(0.48-2.96)‡ |
0.002 |
0.81(0.27-2.39)‡ |
<0.001 |
| Oral |
1 |
0.73 (0.38-1.39) |
0.312 |
1.09 (0.26-4.55)‡ |
0.013 |
1.012(0.30-3.45)‡ |
0.026 |
0.88(0.56-1.36) |
0.478 |
| Ethnicity |
|
|
|
|
|
|
|
|
|
| Asian |
12 |
1.40(1.12- 1.69)‡ |
<0.001 |
1.26(1.02- 1.51)‡ |
<0.001 |
1.18 (1.08-1.55)‡ |
<0.001 |
1.14(0.96-1.36)‡ |
<0.001 |
| European |
5 |
1.13(0.60-1.97)‡ |
0.070 |
0.98 (0.69-1.37)‡ |
0.070 |
1.11(0.76-1.52)‡ |
0.029 |
1.01(0.73 -1.51) |
0.154 |
| Source of Control |
|
|
|
|
|
|
|
|
|
| Population-based |
5 |
1.19(0.91-1.90)‡ |
<0.001 |
1.16 (1.08-1.50)‡ |
0.029 |
1.10(1.01-1.72)‡ |
<0.001 |
0.95 (0.68-1.73)‡ |
<0.001 |
| Hospital-based |
12 |
1.25(1.01 -1.74)‡ |
0.001 |
1.15( 0.88-1.50)‡ |
<0.001 |
1.14(0.84-1.54)‡ |
<0.001 |
0.97 (0.82 -1.39） |
0.150 |
Abbreviations: CI, confidence interval; OR, odds ratio.
* Studies of comparison,﹩P-value of Q-test for heterogeneity test, ‡ Random model was used. |
